02.26.21
The drug pricing debate continues to rage on, both at the federal level – look to H.R. 3, seen in the House in 2019 that imported foreign pricing models, which a recent Congressional Budget Office report acknowledges relied on the Quality-Adjusted Life Year to score savings – and in the states, like in my home state of Massachusetts, where our Health Policy Commission has signed a contract with the Institute for Clinical and Economic Review to develop a…02.08.21
The cost of health care is high. Too high. There is discussion by federal and state lawmakers about policies to lower costs to protect patients and their families. I applaud the intent, but, as the parent of a child with cystic fibrosis (CF) and the leader of a patient advocacy organization, I believe they are missing the mark.
